Since making its first investment in 2013, the DDI has achieved a number of key milestones and is making a significant impact on the drug development environment in Ohio and beyond.

Highlights of key achievements to date include:

  • >100 potential projects/technologies reviewed
  • 14 invested or managed projects
  • 3 projects out-licensed or partnered
  • 1 spin-out company launched
  • 24 publications supported by data from DDI-funded research
  • 28 patents or invention disclosures generated from DDI investment
  • $1.68 million in external grants awarded to investigators based on DDI-supported research
  • 33 postdoctoral fellows, students and interns supported through DDI projects
  • Drug development and commercialization workshops and seminars provided to the academic community

Partnerships and New Ventures

Over a short period, the DDI has established productive partnerships and out-licensed several drug development projects. These partnerships have high-value potential to bring new therapies to patients. Examples are featured below.

Biosortia Pharmaceuticals (Research Collaboration)


December 2015: Biosortia Pharmaceuticals and the OSUCCC − James entered a collaboration providing cancer researchers with access to novel natural products for the purpose of drug development. In conjunction with the DDI, this collaboration will leverage the screening assays and drug development expertise of OSUCCC − James researchers and Biosortia’s proprietary natural product chemistry to identify new therapies. Read more.

Evotec AG (Research Collaboration)


December 2014: The OSUCCC − James and Evotec AG formed a research collaboration to advance a novel mechanism for engaging the important cancer target, Kras. Through this DDI-managed alliance, novel biological discoveries made at Ohio State will be translated into a state-of-the-art drug discovery project. Read more.

Sirona Therapeutics, Inc. (Spin-out Company)


June 2014: The DDI led an effort to partner with Venture Therapeutics, Inc., The Ohio State University and the University of Michigan to commercialize an oral patch for delivery of drugs for the treatment of precancerous lesions. Through the creation of a new spin-out venture, Sirona Therapeutics, Ohio State and Venture Therapeutics are collaborating to complete preclinical studies and initiate clinical trials. This collaboration demonstrates how academia and industry can work together to advance therapies to meet important unmet medical needs. Read more.

To learn more about becoming a partner with the DDI, contact us at ddi@osumc.edu.

Contact the DDI

Email: ddi@osumc.edu
Phone: 614-685-6957